BR100 Increased By (0.01%)
BR30 Increased By (0.16%)
KSE100 Decreased By (-0.03%)
KSE30 Decreased By (-0.02%)
AGHA 6.33 Increased By ▲ 0.01 (0.16%)
BECO 4.27 No Change ▼ 0.00 (0%)
BML 62.70 Increased By ▲ 0.25 (0.4%)
BOP 31.50 Increased By ▲ 0.27 (0.86%)
CNERGY 11.79 Increased By ▲ 0.20 (1.73%)
CSIL 5.94 Increased By ▲ 0.22 (3.85%)
FCCL 60.90 Decreased By ▼ -0.64 (-1.04%)
FFL 15.07 Increased By ▲ 0.05 (0.33%)
FNEL 1.25 Increased By ▲ 0.02 (1.63%)
KEL 6.25 Decreased By ▼ -0.01 (-0.16%)
KOSM 5.57 Increased By ▲ 0.01 (0.18%)
LOTCHEM 24.68 No Change ▼ 0.00 (0%)
MLCF 103.00 Decreased By ▼ -1.08 (-1.04%)
NBP 176.00 Increased By ▲ 0.72 (0.41%)
NCPL 53.40 Increased By ▲ 0.63 (1.19%)
NPL 54.85 Increased By ▲ 0.73 (1.35%)
OGDC 313.69 Increased By ▲ 0.30 (0.1%)
PACE 9.25 Increased By ▲ 0.05 (0.54%)
PAEL 35.66 Decreased By ▼ -0.14 (-0.39%)
PIBTL 13.55 Increased By ▲ 0.08 (0.59%)
PPL 221.50 Decreased By ▼ -0.31 (-0.14%)
PRL 80.88 Increased By ▲ 1.80 (2.28%)
PTC 46.90 Increased By ▲ 0.05 (0.11%)
SSGC 24.04 Increased By ▲ 0.17 (0.71%)
TBL 9.33 Increased By ▲ 0.02 (0.21%)
TELE 7.39 No Change ▼ 0.00 (0%)
TPL 24.79 Decreased By ▼ -0.32 (-1.27%)
TPLP 12.70 Increased By ▲ 0.19 (1.52%)
TREET 26.35 Increased By ▲ 0.10 (0.38%)
TRG 53.43 Decreased By ▼ -0.01 (-0.02%)
By

BRUSSELS: The European Union is ready to help drug companies expand coronavirus vaccine production to clear a "bottleneck" in distribution, its top health official said Saturday.

Health commissioner Stella Kyriakides told German news agency DPA that any delay in getting approved vaccines out was down to production capacity shortage, not EU planning.

"The bottleneck at the moment is not the volume of orders but the worldwide shortage of production capacity," she said, in comments distributed by her office.

Kyriakides noted that Brussels had provided 100 million euros to German firm BioNTech, which developed a vaccine with US giant Pfizer, to help build production capacity.

And she said that the bloc was ready to do more, for Pfizer-BioNTech and other companies with candidate vaccines, as the vaccination campaign gets into gear.

"The situation will improve step by step," she promised, one week after vaccinations began at widely varying paces among EU member states. "We have been negotiating for additional vaccine doses from BioNTech for a long time and are again ready to help expand production capacities. "Other manufacturers with whom we have contracts are on the verge of having their vaccines approved by the EU."

The European Medicines Agency, which advises the European Commission, approved the Pfizer-BioNTech vaccine on December 21.

But it is not expected to rule on a potential alternative from US company Moderna until January 6.

And it is awaiting more data on a candidate from AstraZeneca and Oxford University, which has already been approved in the UK.

But Kyriakides insisted that Europe is not falling behind in its joint procurement programme, backed by the 27 member states.

"If all vaccine candidates are approved, Europe will have more than two billion doses of vaccine available for all 450 million Europeans and their neighbours," she said. "And that's what it's all about: Europe can get out of this crisis fastest together."

Comments

Comments are closed for this article.